Todos Medical Presents Encouraging Scientific Abstract

In Clinical Studies News by Barbara Jacoby



Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early detection of cancer, presented its scientific abstract discussing the most recent clinical trial results of the TM-B1 cancer screen test at the 2018 San Antonio Breast Cancer Symposium (SABCS) earlier today. The TM-B1 cancer screen test, which is designed for women 25 and over, screens for the presence of breast cancer. The study consisted of 190 women, including 50 women with breast cancer (including DCIS).

“We are extremely pleased with the results of our latest clinical trial,” said Herman Weiss, MD, FACOG, MBA, CEO of Todos Medical. “The TM-B1 cancer screen test achieved an overall sensitivity of 86% and specificity of 98% for breast cancer detection in the general population, and interestingly, an 83% sensitivity and 99% specificity was recorded for women with dense breasts (about 55% of study population). In comparison, screening mammography, the most commonly used imaging modality, has a sensitivity and specificity of approximately 80%, and even less in dense breast tissue. These results demonstrate the ability of Todos Medical to offer game-changing technology for the early detection of breast cancer in all women, including those who present challenges to existing screening methods. The potential to save lives is compelling.”

“Our TM-B1 breast cancer screen test, in conjunction with current imaging techniques, may contribute to the early detection of breast cancer by increasing sensitivity and reducing false positive results and unnecessary biopsies,” said Todos Medical Chief Technology Officer Udi Zelig, PhD. “With further studies with larger numbers we hope to validate and establish the utility of adding the TM-B1 cancer screen test to current standard screening for breast cancer. It’s quite an exciting prospect.”

About Todos Medical Ltd.

Todos Medical Ltd. (OTCQB: TOMDF) headquartered in Rehovot, Israel, is a cancer in-vitro-diagnostic (“IVD”) company engaging in the development of a series of blood tests for the early detection of a variety of cancers. The company has developed two cancer screening tests based on TBIA (Todos Biochemical Infrared Analyses), a method for cancer screening using peripheral blood analysis. The TBIA screening method is based on the cancer’s influence on the immune system which triggers biochemical changes in peripheral blood mononuclear cells (“PBMC”) and plasma. This proprietary and patented method incorporates biochemistry, physics and signal processing. The company’s two cancer screening tests, TM-B1 and TM-B2 are CE marked in the EU.

For more information, the content of which is not part of this press release, please visit

Forward-looking statements: Certain statements contained in this press release may constitute forward-looking statements. For example, we use forward-looking statements when discussing our expected clinical development programs and clinical trials. These forward-looking statements are based only on the current expectations of the management of Todos Medical, and are subject to significant risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; and laboratory results that do not translate to equally good results in real settings, all of which could cause the actual results or performance of Todos Medical to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Todos Medical undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Todos Medical, reference is made to Todos Medical’s reports filed from time to time with the U.S. Securities and Exchange Commission.